Mouse anti PSMA

MAb 107-1A4 could not be used in Western blot, is useful for immunohistochemistry on frozen and paraffin-embedded tissues, immunocytochemistry, flow cytometry and ELISA. Optimal antibody dilution should be determined by titration; recommended range is 1:100 ? 1:1000 for immunohistochemistry with avidin-biotinylated Horseradish peroxidase complex (ABC) as detection reagent.

Prostate specific antigen (PSA) is the most widely used marker of prostate cancer. Immunoassays for PSA using monoclonal (MAb) or polyclonal antibodies have clinical appliCations, such as monitoring and early detection of prostate cancer. However, PSA is not a perfect tumor marker because Serum levels often are elevated in men with benign prostatic hyperplasia, prostatitis and other nonmalignant disorders and also because levels are not always elevated in individuals with early prostate cancer. 107-1A4 is a new prostate cancer-reactive MAb which can identify additional proteins that could be of value for the diagnosis and treatment of prostate cancer. It shows selective reactivity to prostate epithelial membrane antigens.

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.

Cancer

Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.

Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.

107.1A4 is a Mouse monoclonal IgG1/k antibody derived by fusion of SP2/0-Ag14 Mouse myeloma cells with spleen cells from an immunized Mouse, using a two-phase immunization protocol involving the prostate cancer cell line LNCaP.

107.1A4 recognizes an antigen, which appeared to be distinct from those previously described and shows specific tumor targeting in preliminary in vivo studies. MAb 107-1A4 is suggested to recognize a distinct conformational and unique epitope in the extracellular domain of PSMA. PSMA is a type II membrane glycoprotein of 100kDa that has a short intracellular N-terminal domain (residues 1 to 18), a transmembrane region (residues 19 to 43) and a large extracellular domain consisting of residues 44 to 750.